Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

BACKGROUND: Doxycycline is often used for treating COVID-19 respiratory symptoms in the community despite an absence of evidence from clinical trials to support its use. We aimed to assess the efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse o...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Christopher C, Yu, Ly-Mee, Dorward, Jienchi, Gbinigie, Oghenekome, Hayward, Gail, Saville, Benjamin R, Van Hecke, Oliver, Berry, Nicholas, Detry, Michelle A, Saunders, Christina, Fitzgerald, Mark, Harris, Victoria, Djukanovic, Ratko, Gadola, Stephan, Kirkpatrick, John, de Lusignan, Simon, Ogburn, Emma, Evans, Philip H, Thomas, Nicholas P B, Patel, Mahendra G, Hobbs, F D Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315758/
https://www.ncbi.nlm.nih.gov/pubmed/34329624
http://dx.doi.org/10.1016/S2213-2600(21)00310-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315758/
https://www.ncbi.nlm.nih.gov/pubmed/34329624
http://dx.doi.org/10.1016/S2213-2600(21)00310-6

Ejemplares similares